Remove tag covid-vaccine
article thumbnail

STAT+: Lawmakers tell Pfizer CEO to ‘back off’ on planned price hike for Covid-19 vaccine

STAT

lawmakers wrote Pfizer chief executive officer Albert Bourla that he should “back off” from plans to charge Americans up to $130 for the company’s Covid-19 vaccine, a move they described as “pure and deadly greed.” A pair of U.S. ” In their letter, U.S. Elizabeth Warren (D-Mass.)

Vaccines 224
article thumbnail

Scientists and medics turn to TikTok to reassure public on vaccine safety

pharmaphorum

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PharmaShots Weekly Snapshots (February 20 - 24, 2023)

PharmaShots

Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

Pharma’s go-to-market strategies have tended to be more traditional than those seen in non-regulated sectors, but there are some signs this is changing, with an acceleration in the pace of change forced by the COVID-19 pandemic that is allowing the industry to close its gap with faster, more nimble consumer brands. Jeremy Richter, Tag.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S.

article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. There is no easy answer to the question of how to incentivise innovation without restricting access.